DepYmed Inc. has announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) to begin phase 1 clinical trials for DPM-1003.

Recce Pharmaceuticals has recently completed a new phase of clinical trials for its lead drug candidate, RECCE® 327.

The trial is assessing the efficacy of Deltacel™ (KB-GDT-01), an allogeneic, readily available Gamma Delta T-cell (GDT) therapy for patients with stage 4 metastatic non-small cell lung cancer (NSCLC).

Biotechnology firm Jasper Therapeutics has initiated its Phase 1b/2a clinical trial, for the treatment of chronic inducible urticaria (CIndU) using a novel antibody, briquilimab.

Celularity Inc. has submitted an application to the U.S. Food and Drug Administration (FDA) for orphan drug designation for PDA-002, its placental-derived cell therapy.

A clinical trial has been initiated for an innovative drug candidate, 23ME-01473, developed by 23andMe Holding Co., a prominent entity in human genetics and biopharmaceuticals.

Significant advancements have been observed in the treatment of thyroid eye disease (TED) with lonigutamab, a humanized monoclonal antibody.

Inhalon Biopharma, a company in the clinical stage, has revealed initial findings from a pivotal Phase 1b clinical trial.

Antennova, a biopharmaceutical firm, has reached a significant milestone with the completion of the initial dosing group in a Phase I clinical trial for ATN-031.

Public Health Vaccines has initiated a Phase 1 clinical trial for a novel vaccine candidate, PHV01, which targets the Marburg virus.

Theratechnologies Inc., has progressed to a higher dosage level in the third phase of its clinical trial for a drug called sudocetaxel zendusortide.

Blue Lake Biotechnology has released early findings from a Phase 1/2a clinical trial for BLB201.